Pascal Demoly

Summary

Country: France

Publications

  1. ncbi [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]
    Pascal Demoly
    Service des Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34
    Presse Med 32:1066-73. 2003
  2. ncbi [Drug allergies: management and current aspects]
    P Demoly
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier
    Presse Med 27:1406-11. 1998
  3. ncbi [Diagnosis of drug allergy]
    P Demoly
    Maladies Respiratoires, INSERM U454-IFR3, , CHU de Montpellier, France
    Rev Mal Respir 19:260-2. 2002
  4. ncbi Anaphylaxis to antitetanus toxoid serum
    P Demoly
    Maladies Respiratoires, INSERM U454, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 57:860-1. 2002
  5. ncbi The place of spirometry in the diagnosis of asthma in those suffering from allergic rhinitis: a pilot study
    P Demoly
    Exploration des Allergies, Service des Maladies Respiratoires, INSERM U454 -- IFR3, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 60:1089-90. 2005
  6. ncbi Managing asthma during pregnancy
    Pascal Demoly
    Exploration des Allergies-Maladies Respiratoires, INSERM U454, , University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 365:1212-3. 2005
  7. ncbi Anaphylactic reactions--value of skin and provocation tests
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier, France
    Toxicology 209:221-3. 2005
  8. ncbi Update on beta-lactam allergy diagnosis
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Curr Allergy Asthma Rep 5:9-14. 2005
  9. ncbi Classification and epidemiology of hypersensitivity drug reactions
    Pascal Demoly
    Allergy Department, Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Immunol Allergy Clin North Am 24:345-56, v. 2004
  10. ncbi Asthma therapy during pregnancy
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires INSERM U454, Hopital Arnaud de Villeneuve, Institut Universitaire de Recherche Clinique de Montpellier, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Expert Opin Pharmacother 4:1019-23. 2003

Detail Information

Publications105 found, 100 shown here

  1. ncbi [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]
    Pascal Demoly
    Service des Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34
    Presse Med 32:1066-73. 2003
    ..In order to gain knowledge on the management of perennial allergic rhinitis by the practitioners in France, a survey (Enquête épidémiologique sur la rhinite allergique per-annuelle en pratique quotidienne--ERAP) was developed...
  2. ncbi [Drug allergies: management and current aspects]
    P Demoly
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier
    Presse Med 27:1406-11. 1998
    ..However, a precise diagnosis is required in order to set up prevention measures. We focus here on some basic and new data concerning these reactions, in particular epidemiological studies, mechanisms and diagnostic methods...
  3. ncbi [Diagnosis of drug allergy]
    P Demoly
    Maladies Respiratoires, INSERM U454-IFR3, , CHU de Montpellier, France
    Rev Mal Respir 19:260-2. 2002
  4. ncbi Anaphylaxis to antitetanus toxoid serum
    P Demoly
    Maladies Respiratoires, INSERM U454, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 57:860-1. 2002
  5. ncbi The place of spirometry in the diagnosis of asthma in those suffering from allergic rhinitis: a pilot study
    P Demoly
    Exploration des Allergies, Service des Maladies Respiratoires, INSERM U454 -- IFR3, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 60:1089-90. 2005
  6. ncbi Managing asthma during pregnancy
    Pascal Demoly
    Exploration des Allergies-Maladies Respiratoires, INSERM U454, , University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 365:1212-3. 2005
  7. ncbi Anaphylactic reactions--value of skin and provocation tests
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier, France
    Toxicology 209:221-3. 2005
    ..These tools are currently being evaluated by the European Network of Drug Allergy, under the aegis of the EAACI drug hypersensitivity group of interest...
  8. ncbi Update on beta-lactam allergy diagnosis
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Curr Allergy Asthma Rep 5:9-14. 2005
    ..In this review, we describe the general guidelines for evaluating subjects in whom there is suspicion of allergic reactions to beta-lactams...
  9. ncbi Classification and epidemiology of hypersensitivity drug reactions
    Pascal Demoly
    Allergy Department, Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Immunol Allergy Clin North Am 24:345-56, v. 2004
    ..True epidemiologic data are limited, and most of the available information on the incidence, mortality, and socioeconomic impact should be discussed with caution...
  10. ncbi Asthma therapy during pregnancy
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires INSERM U454, Hopital Arnaud de Villeneuve, Institut Universitaire de Recherche Clinique de Montpellier, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Expert Opin Pharmacother 4:1019-23. 2003
    ..Usually, there is at least one 'safe' drug from each major class used to control symptoms. We will review the current literature on this subject...
  11. ncbi Successful docetaxel tolerance induction
    D Messaad
    Maladies Respiratoires, INSERM U454, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 58:1320-1. 2003
  12. ncbi Treatment of allergic rhinitis during pregnancy
    Pascal Demoly
    Department of Respiratory Medicine, INSERM U454, Hospital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Cedex 5 Montpellier, France
    Drugs 63:1813-20. 2003
    ..There are no such data available for intra-nasal decongestants. Finally, pregnancy is not considered as a contraindication for the continuation of allergen specific immunotherapy...
  13. ncbi Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions
    Said Benahmed
    Exploration des Allergies Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU Montpellier, 34295 Montpellier Cedex 5, France
    Eur J Clin Pharmacol 61:537-41. 2005
    ..A firm diagnosis of drug hypersensitivity, because it may re-induce the reaction, is seldom confirmed. Causality assessment algorithms are therefore of interest...
  14. ncbi [Identifying and understanding drug allergies]
    Pascal Demoly
    Inserm U 454 IFR3, Hopital Arnaud de Villeneuve, Avenue Gaston Giraud, 34295 Montpellier, France
    Med Sci (Paris) 19:327-36. 2003
    ....
  15. ncbi [Respiratory allergic disease genes]
    P Demoly
    Service des Maladies Respiratoires, Inserm U 454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5
    Rev Pneumol Clin 59:67-75. 2003
    ..Research will continue to define these genes more precisely or to recognize others and to apply this knowledge to therapeutic and diagnostic applications...
  16. ncbi [Allergy to macrolides. 21 cases]
    P Demoly
    Maladies Respiratoires, Hôpital Amaud de Villeneuve, Montpellier
    Presse Med 29:294-8. 2000
    ..Allergic drug reactions to macrolides are extremely rare and there is little information in the literature concerning relevant diagnostic tests...
  17. ncbi [Allergy to macrolide antibiotics. Review of the literature]
    P Demoly
    INSERM U454 IFR3, Hôpital Amaud de Villeneuve, CHU de Montpellier
    Presse Med 29:321-6. 2000
    ..It would appear that macrolide allergies are unlikely to be class allergies. This is important as eviction advice could be limited to the single causal macrolide...
  18. ncbi [Asthma and rhinitis medications: pregnancy precautions]
    P Demoly
    INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier
    Presse Med 29:1625-9. 2000
    ..Indeed, it would be regrettable to be too prudent and deprive symptomatic patients of active treatments. Patients should be clearly informed of the benefits and risks of drug therapy...
  19. ncbi [Genetics of asthma and atopy]
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier
    J Soc Biol 194:39-42. 2000
    ..Much of the information available today has been fragmentary and not always confirmed. Alleles at multiple loci are likely to be involved and the ultimate picture is most likely determined by many genetic and environmental factors...
  20. ncbi [From allergic rhinitis to sinus diseases (sinusitis/nasal polyps): epidemiologic and experimental links]
    P Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, Service d ORL, Hopital Gui de Chauliac, CHU de Montpellier
    Rev Mal Respir 17:925-30. 2000
    ..Because the diagnosis of allergic rhinitis provides useful therapeutic options, an appropriate evaluation for underlying allergies in indicated in any patient with chronic upper respiratory tract symptoms...
  21. ncbi Safety of intranasal corticosteroids in acute rhinosinusitis
    Pascal Demoly
    Clinical Department of Allergology, Maladies Respiratoires, INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Am J Otolaryngol 29:403-13. 2008
    ....
  22. ncbi [Drug allergies and drug hypersensitivities]
    Pascal Demoly
    Unité d Exploration des Allergies, maladies respiratoires Inserm, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5
    Rev Prat 57:1326-30. 2007
    ..Biological tests are being evaluated. When properly performed in specialised centres, a firm diagnosis is often possible and safe alternative medication can be proposed...
  23. ncbi Epidemiology of drug allergy
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 1:305-10. 2001
    ..Therefore, there are few true epidemiological data, and most of those that are available, including incidence, mortality and socioeconomic impact data, should be interpreted with caution...
  24. ncbi The relation between asthma and allergic rhinitis
    Pascal Demoly
    Exploration des Allergies-Maladies Respiratoires-INSERM U454, , University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 368:711-3. 2006
  25. ncbi [Nasal allergy and asthma: one or two diseases?]
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier cedex 05
    Bull Acad Natl Med 189:1461-73. 2005
    ....
  26. ncbi Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions
    Said Benahmed
    Exploration des Allergies, Maladies Respiratoires, , , Montpellier, France
    Arch Intern Med 165:1500-5. 2005
    ..CONCLUSION: A pharmacovigilance algorithm is not accurate for the diagnosis of drug hypersensitivity reactions and cannot replace drug allergy testing...
  27. ncbi [Hypersensitivity to insulin]
    Djamel Messaad
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU, Montpellier
    Presse Med 33:631-8. 2004
    ..Finally, the switch to another insulin or even a tolerance induction with the least skin test reactive insulin as a last resource. The most severe systemic reactions are an indication for tolerance induction...
  28. ncbi Budesonide/formoterol maintenance and reliever therapy versus conventional best practice
    Pascal Demoly
    University Hospital of Montpellier and INSERM U, Hopital Arnaud de Villeneuve, France
    Respir Med 103:1623-32. 2009
    ..29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP...
  29. ncbi Epidemiology of hypersensitivity drug reactions
    Eva Rebelo Gomes
    Allergy Department, INSERM U454 - IFR3, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 5:309-16. 2005
    ..Such studies will be helpful in identifying patients at risk of developing such reactions, in particular severe reactions, and implementing early preventive measures...
  30. ncbi Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey
    Silvia Caimmi
    Exploration des Allergies, Clinique des Maladies Respiratoires and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, France
    Int Arch Allergy Immunol 153:53-60. 2010
    ..In patients sensitized to beta-lactams, a safe beta-lactam alternative is often needed. The objective was to assess the safety of cefuroxime in patients with a proven beta-lactam allergy...
  31. ncbi How Can We Better Classify NSAID Hypersensitivity Reactions? - Validation from a Large Database
    Silvia Caimmi
    Allergy Department and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Int Arch Allergy Immunol 159:306-12. 2012
    ..It allows clinicians to identify patients at a high risk, based on the clinical history and clinical manifestations. Moreover, it is helpful for a better understanding and teaching of these reactions...
  32. ncbi The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article
    Philippe J Bousquet
    Department of Respiratory Diseases, University Hospital of Montpellier, Montpellier, France
    J Allergy Clin Immunol 127:49-56, 56.e1-11. 2011
    ..Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials...
  33. ncbi Confirmation of the diagnosis of natural rubber latex allergy by the Basotest method
    Marie Laure Hemery
    Unit, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Int Arch Allergy Immunol 136:53-7. 2005
    ..The aim of this study was to evaluate the performance (specificity and sensitivity) of Basotest in the diagnosis of natural rubber latex allergy...
  34. ncbi Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper
    J Bousquet
    University Hospital and INSERM, Montpellier, France
    Allergy 63:842-53. 2008
    ..It is likely that neuronal mechanisms, T cells, innate immunity and possibly auto-immune responses all play a role in NAR and may also contribute to the symptoms of allergic rhinitis...
  35. ncbi Clinical presentation and time course in hypersensitivity reactions to beta-lactams
    P J Bousquet
    Exploration des Allergies, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, University Hospital of Montpellier INSERM U454 IFR3, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 62:872-6. 2007
    ..beta-lactam hypersensitivity reactions are classified as immediate or nonimmediate. Diagnosis is usually based upon skin tests and provocation challenges...
  36. ncbi [Allergen-specific immunotherapy or desensitization]
    Pascal Demoly
    Unité d Exploration des Allergies, Maladies Respiratoires, Hopital Arnaud de Villeneuve, CHU de Montpellier et Inserm U657, 34295 Montpellier Cedex 5, France
    Bull Acad Natl Med 193:1127-44; discussion 1144-5. 2009
    ..More information is also needed on patient selection, the treatment duration, and dosing schedules...
  37. ncbi Update in drug allergy: novel drugs with novel reaction patterns
    Marta Rubio
    Allergy Department and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 10:457-62. 2010
    ..This review summarizes current knowledge on the epidemiology, mechanisms, and clinical and in-vitro diagnosis of these reactions...
  38. ncbi Desloratadine for the treatment of cypress pollen-induced allergic rhinitis
    Pascal Demoly
    Allergy Department, INSERM U657, Maladies Respiratoires, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Ann Allergy Asthma Immunol 103:260-6. 2009
    ..Few studies have been conducted to assess treatment options for patients with sensitivities to cypress pollens, important triggers of allergic rhinitis (AR) in the Mediterranean region...
  39. ncbi Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction
    Djamel Messaad
    Hopital Arnaud de Villeneuve, Montpellier, France
    Ann Intern Med 140:1001-6. 2004
    ..CONCLUSIONS: Drug provocation tests in individuals with suspected drug allergy performed in carefully controlled settings can confirm drug hypersensitivity...
  40. ncbi Unmet needs in severe chronic upper airway disease (SCUAD)
    Jean Bousquet
    University Hospital, Montpellier, France
    J Allergy Clin Immunol 124:428-33. 2009
    ..This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases...
  41. ncbi Drug hypersensitivity: epidemiology and risk factors
    L Guglielmi
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Curr Pharm Des 12:3309-12. 2006
    ..The chemical properties of the drug and the treatment regimen also influence the development of drug allergies...
  42. ncbi Specific immunotherapy in rhinitis and asthma
    J Bousquet
    Service des Maladies Respiratoires, INSERM U454 Hĵpital Arnaud de Villeneuve, Montepelier, France
    Ann Allergy Asthma Immunol 87:38-42. 2001
    ....
  43. ncbi Prospects for a vaccine in allergic diseases and asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, INSERM V454, Montpellier, France
    BioDrugs 13:61-75. 2000
    ..Nonspecific approaches include humanised anti-IgE antibodies,moderation of the T(H)2 cytokine network and antisense oligodeoxynucleotide therapy...
  44. ncbi Drug hypersensitivities: definition, epidemiology and risk factors
    P Demoly
    Allergy Department, Maladies Respiratoires and INSERM U454, IFR3, , University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Allerg Immunol (Paris) 37:202-6. 2005
    ..Future progress in genetics can help the identification of populations at risk for specific reactions. This review describes currently known data on incidence,prevalence, mor tality and risk factors of these reactions...
  45. ncbi [Recommendations for the management of asthma]
    J Bousquet
    Service des Maladies Respiratoires, CHU Monptellier, INSERM U454, Hôpital Arnaud de Villeneuve 34 295 Montpellier
    Rev Prat 51:533-7. 2001
    ..These guidelines are applied in over 100 countries worldwide, and, in countries where they are applied, morbidity and mortality due to asthma have decreased...
  46. ncbi National survey on the management of rhinopathies in asthma patients by French pulmonologists in everyday practice
    P Demoly
    Maladies Respiratoires, INSERM U454-IFR3, , University of Montpellier, France
    Allergy 58:233-8. 2003
    ..Thus, our findings support one of the central messages contained in the new ARIA guidelines-asthma patients should be investigated routinely for rhinitis and other rhinopathies...
  47. ncbi Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier Cedex 5, France
    Allergy 65:1212-21. 2010
    ..Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved...
  48. ncbi Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication
    Olivier Mathieu
    Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Régional Universitaire de Montpellier, 191, Avenue Gaston Giraud, 34295 Montpellier Cedex 5, France
    Pharmacol Rep 63:86-94. 2011
    ....
  49. ncbi Montelukast in guidelines and beyond
    Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 371 Avenue Doyen Gaston Giraud, 34275 Montpellier, Cedex 5, France
    Adv Ther 26:575-87. 2009
    ..This review includes new studies that have not yet been considered in guidelines...
  50. ncbi Immunotherapy: clinical trials--optimal trial and clinical outcomes
    Philippe Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier, France
    Curr Opin Allergy Clin Immunol 7:561-6. 2007
    ..Although specific immunotherapy was introduced a century ago, very few trials meet the criteria for pivotal studies. The paper reviews the methods which should be used to investigate specific immunotherapy...
  51. ncbi Drug allergy diagnosis work up
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, , CHU de Montpellier, F-34295 Montpellier, France
    Allergy 57:37-40. 2002
    ..These tools are currently being evaluated by the European Network of Drug Allergy, under the aegis of the EAACI drug hypersensitivity group of interest...
  52. ncbi ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France
    Pascal Demoly
    Service des Maladies Respiratoires, , CHU de Montpellier, France
    Allergy 57:546-54. 2002
    ..General practitioners play a major role in this disorder; they make the diagnosis, start the treatment, give the relevant information, and monitor most of the patients...
  53. ncbi Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions
    B Lebel
    Maladies Respiratoires, INSERM U454 - IFR3, CHU de Montpellier, Montpellier Cedex, France
    Allergy 56:688-92. 2001
    ..The efficiency of both tests was low. CONCLUSION: Thus, in most cases, the in vitro Cys-LT test has little or no diagnostic utility and is not superior to histamine release...
  54. ncbi ARIA (Allergic Rhinitis and Its Impact on Asthma) classification of allergic rhinitis severity in clinical practice in France
    P J Bousquet
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
    Int Arch Allergy Immunol 143:163-9. 2007
    ..The Allergic Rhinitis and Its Impact on Asthma (ARIA) workshop proposes a classification of allergic rhinitis severity. It does not take into account impairment in quality of life and treatment should be adapted accordingly...
  55. ncbi Physician and patient survey of allergic rhinitis in France: perceptions on prevalence, severity of symptoms, care management and specific immunotherapy
    P Demoly
    Unité d Exploration des Allergies, INSERM U657 Hôpital Arnaud de Villeneuve, Montpellier, France
    Allergy 63:1008-14. 2008
    ..A telephone survey of patients and physicians in France was carried out to understand better the real and perceived advantages and inconveniences of this therapeutic approach...
  56. ncbi Validation of the classification of ARIA (allergic rhinitis and its impact on asthma)
    P Demoly
    , Service des Maladies Respiratoires, INSERM, , Montpellier Cedex, France
    Allergy 58:672-5. 2003
    ..CONCLUSIONS: The proposal of the ARIA expert panel defining the chronology of allergic rhinitis as number of days per week and consecutive weeks per year is likely to change daily physician practice...
  57. ncbi Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy
    C Fontaine
    Exploration des allergies Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Allergy 62:47-52. 2007
    ..They can be explored by in vivo and/or in vitro tests. The measurement of serum-specific immunoglobulin E (IgE) presents several advantages: safety, simplicity, and availability to nonallergologist physicians...
  58. ncbi Allergic rhinitis management pocket reference 2008
    J Bousquet
    Allergic Rhinitis and its Impact on Asthma, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Allergy 63:990-6. 2008
    ..This document will be a major resource in this educational program...
  59. ncbi Allergen-induced mediator release tests
    P Demoly
    Maladies Respiratoires - INSERM U454, CHU de Montpellier, Cedex, France
    Allergy 58:553-8. 2003
    ..In this review, we will detail allergen-dependent histamine, tryptase, arachidonic acid metabolite, e.g. cysteinyl leukotrienes and 15-hydroxyeicosatetraenoic mediator release tests...
  60. ncbi Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics
    Silvia Caimmi
    Allergy Unit, Deépartement de Pneumologie et Addictologie, Hopital Arnaud de Villeneuve, University Hospital of Montpellier and Inserm U657, 37, avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
    Clin Transl Allergy 2:10. 2012
    ..abstract:..
  61. ncbi [Contribution of epidemiology to the prevention of drug allergies]
    Pascal Demoly
    Pneumologie et Addictologie, INSERM U657, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Bull Acad Natl Med 195:1335-42; discussion 1342-4. 2011
    ..This review examines the place of interventional epidemiology in the field of drug allergy, taking as examples both myorelaxant-induced anaphylaxis and abacavir-induced DRESS...
  62. ncbi IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene
    Jerome Pene
    Institut National de la Sante et de la Recherche Medicale, Unite 454, Centre Hospitalier Universitaire St Eloi, Montpellier, France
    J Immunol 177:5006-13. 2006
    ....
  63. ncbi Overexpression of the human glucocorticoid receptor alpha and beta isoforms inhibits AP-1 and NF-kappaB activities hormone independently
    Claire Gougat
    , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    J Mol Med 80:309-18. 2002
    ..This property was not shared by the closely related mineralocorticoid receptor. Our results suggest that overexpression of either GRalpha or GRbeta may have an anti-inflammatory effect...
  64. ncbi [Drug allergy and hypersensitivity. Risk factors]
    Pascal Demoly
    Exploration des Allergies - Maladies Respiratoires, INSERM, , avenue du Doyen Gaston Giraud, 34295 Montpellier 5, France
    Bull Acad Natl Med 190:1733-42; discussion 1742-4. 2006
    ..An ongoing study by our group points to a role of polymorphisms within the IL-10 promoter and in the IL-4Ralpha gene in immediate reactions to beta-lactams...
  65. ncbi Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols
    H B Co-Minh
    Dermatology Unit, St Eloi Hospital 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Allergy 62:92-3. 2007
    ..We reported an anaphylaxis after oral intake and contact urticaria due to polyethylene glycols...
  66. ncbi Spreading and impact of the World Health Organization's Allergic Rhinitis and its impact on asthma guidelines in everyday medical practice in France. Ernani survey
    P Demoly
    Allergy Department, University Hospital of Montpellier and Inserm U657, Hopital Arnaud de Villeneuve, 34295 Montpellier cedex 05, France
    Clin Exp Allergy 38:1803-7. 2008
    ..The aim of this study was to determine the spreading level of the WHO-ARIA (World Health Organization's Allergic Rhinitis and its Impact on Asthma) guidelines among the medical community and their influence on medical practices...
  67. ncbi Important questions in Allergy: 1--drug allergy/hypersensitivity
    P Demoly
    Exploration des Allergies - Inserm U657, , University Hospital of Montpellier, Montpellier, France
    Allergy 63:616-9. 2008
  68. ncbi Selective hypersensitivity to pidolate
    N Raison-Peyron
    Maladies Respiratoires, INSERM U454 - IFR3, , France
    Allergy 57:53-4. 2002
  69. ncbi The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial
    S Benahmed
    Maladies Respiratoires, INSERM U454, , CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 59:1130-3. 2004
  70. ncbi Latex is not essential in a standardized skin prick test battery
    P J Bousquet
    University Hospital, Allergy, Montpellier, France
    Allergy 60:407-8. 2005
  71. ncbi Isolated urticaria to ondansetron and successful treatment with granisetron
    P J Bousquet
    Exploration des Allergies, Maladies Respiratoires, INSERM U454, , University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 60:543-4. 2005
  72. ncbi The diagnosis of asthma using a self-questionnaire in those suffering from allergic rhinitis: a pharmaco-epidemiological survey in everyday practice in France
    P Demoly
    Exploration des Allergies - Maladies Respiratoires and INSERM U454 - IFR3, , University Hospital of Montpellier, Montpellier Cedex, France
    Allergy 61:699-704. 2006
    ..15-1.37), and patient age (<or=25 vs >47) (OR=0.73; 95% CI=0.65-0.80). CONCLUSION: Asthma symptoms are frequent in rhinitics without a prior history of asthma. Several variables were shown to be predictive of asthma in these patients...
  73. ncbi Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
    J Bousquet
    University Hospital and INSERM, , Montpellier, France
    Allergy 63:8-160. 2008
  74. ncbi [GA2LEN (Global Allergy and Asthma European Network)]
    J Bousquet
    CHU, Hopital Arnaud de Villeneuve, INSERM U780, Montpellier, France
    Rev Mal Respir 26:577-86. 2009
    ..The major achievements of GA2LEN are reported in this paper...
  75. ncbi Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab
    C Galera
    Allergy and Respiratory Diseases Unit, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    J Investig Allergol Clin Immunol 19:225-9. 2009
    ..AntiIgE has provided a treatment option for patients with severe IgE-mediated allergic disease that is difficult to treat. This case suggests that omalizumab may be able to prevent anaphylaxis during immunotherapy...
  76. ncbi IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women
    L Guglielmi
    INSERM U454, CHU Arnaud de Villeneuve, Montpellier
    Allergy 61:921-7. 2006
    ..Allergic reactions to beta-lactam antibiotics represent the most frequent cause of immunological drug reactions...
  77. ncbi Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
    H Peyriere
    Department of Medical Pharmacology, University Hospital of Montpellier, Hopital Lapeyronie, 971 avenue du doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Br J Dermatol 155:422-8. 2006
    ....
  78. ncbi Clinical value of negative skin tests to iodinated contrast media
    S Caimmi
    Exploration des Allergies, Maladies Respiratoires and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Clin Exp Allergy 40:805-10. 2010
    ..Several studies have shown that skin tests are useful tools for the diagnosis of iodinated contrast medium (ICM) allergy, but the real number of false negative results is not known...
  79. ncbi Validation of a questionnaire for assessment of asthma patient knowledge and behaviour
    F Trebuchon
    University Hospital of Montpellier and Inserm U657, Montpellier, France
    Allergy 64:62-71. 2009
    ..However, no tool is available to assess change in patient knowledge and behaviour before and after completing an educational programme...
  80. ncbi JLP5B9: new monoclonal antibody against polysialylated neural cell adhesion molecule is of value in phenotyping lung cancer
    M Del Rio
    CNRS UMR 9921, Centre de Recherche en Cancerologie, CRLC Val d Aurelle, Montpellier, France
    J Immunol Methods 233:21-31. 2000
    ..This mAb deserves further investigation to evaluate its potential as a tool for serodiagnosis of lung cancer...
  81. ncbi Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study
    J Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 64:1516-23. 2009
    ..There is no placebo-controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first-line treatment of seasonal and perennial allergic rhinitis...
  82. ncbi Endoscopic surgical treatment of sinonasal polyposis-medium term outcomes (mean follow-up of 5 years)
    R Garrel
    Department of Otolaryngology, CHU Montpellier, France
    Rhinology 41:91-6. 2003
    ..Between 30 and 50% of patients with sinonasal polyposis (SNP) will require surgical treatment...
  83. ncbi [Specific immunotherapy for respiratory allergies. A modern treatment]
    M Ndiaye
    Service des Maladies Respiratoires, Exploration des Allergies, INSERM U454-IFR3, , CHU de Montpellier
    Presse Med 32:1508-16. 2003
    ..A greater use of the sublingual route, together with biological and clinical research will allow the widening of its indications...
  84. ncbi Control and exacerbation of asthma: a survey of more than 3000 French physicians
    P Demoly
    Clinique des Maladies Respiratoires-INSERM U454, , CHU Montpellier, Cedex, France
    Allergy 59:920-6. 2004
    ..CONCLUSIONS: This survey emphasizes the complexity of the notions of asthma control and exacerbation and provides novel informations to orient continuing education programmes...
  85. ncbi [Skin testing with respiratory allergens: which techniques, which extracts, which battery?]
    V Piette
    Maladies Respiratoires, INSERM U454 IFR3, CHU de Montpellier, Montpellier, France
    Rev Mal Respir 19:529-31. 2002
  86. ncbi Prick tests to aeroallergens: is it possible simply to wipe the device between tests?
    V Piette
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, France
    Allergy 57:940-2. 2002
    ....
  87. ncbi Immunotherapy with keyhole lampet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy
    P Demoly
    Maladies Respiratoires, , Montpellier, France
    Clin Exp Allergy 32:1071-6. 2002
    ..There was no significant difference in total symptom scores between the placebo and vaccine groups. The vaccine was safe. CONCLUSIONS: The KLH-conjugated decapeptide vaccine was not effective in cypress pollen allergy...
  88. ncbi Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils
    V Kvedariene
    INSERM U454-IFR3, , Montpellier Cedex, France
    Allergy 61:311-5. 2006
    ..The specificity was 93.3%. CONCLUSION: Basotest may be useful for the diagnosis of NMBA allergy in patients with a suspicion of recent IgE-mediated hypersensitivity reaction to NMBA...
  89. ncbi Long-term safety and efficacy of nevirapine tolerance induction
    D Messaad
    Maladies Respiratoires, , Montpellier University Hospital, France
    Clin Exp Allergy 32:733-5. 2002
    ..CONCLUSION: Therefore, when no alternatives are available in severely ill and hypersensitive HIV-infected patients, tolerance induction is a possible therapeutic option...
  90. ncbi Links between rhinitis and asthma
    J Bousquet
    Clinique des Maladies Respiratoires and INSERM U454, , CHU Montpellier, France
    Allergy 58:691-706. 2003
    ..Subjects with allergic rhinitis have an increased risk of developing asthma and may form a suitable population for secondary intervention to interrupt the 'allergic march'...
  91. ncbi Oral challenges are needed in the diagnosis of beta-lactam hypersensitivity
    P J Bousquet
    Exploration des Allergies, Maladies Respiratoires and INSERM, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Clin Exp Allergy 38:185-90. 2008
    ..Standardized European Network for Drug Allergy questionnaires, skin test and challenge procedures were followed...
  92. ncbi [A revised nomenclature for allergy]
    P Meyer
    Service d'explorations des allergies, Maladies Respiratoires, INSERM U454, CHU de Montpellier, , France
    Arch Pediatr 11:1131-4. 2004
    ..We will review here, as faithfully as possible, the distinct definitions and the right terms to use in allergy and in the other medical branches...
  93. ncbi [Smoking habits, attitudes and knowledges of medical students of Medicine, Pharmacy and Odonto-Stomatology's Faculty of Dakar, Senegal]
    M Ndiaye
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Rev Mal Respir 20:701-9. 2003
    ..Smoking is a public health problem that does not spare the medical profession. We set out to determine the prevalence of smoking in medical students in Dakar and to assess their attitudes and knowledge in the face of this problem...
  94. ncbi Towards evidence-based practice of allergy and clinical immunology: applying an evidence-based medicine approach to allergen avoidance
    Henry Milgrom
    Curr Opin Allergy Clin Immunol 3:155-7. 2003
  95. ncbi Drug allergies--unknown dangers to patients
    Pascal Demoly
    Expert Opin Drug Saf 7:347-50. 2008
    ..RESULTS/CONCLUSION: Drug hypersensitivity reactions are not so rare adverse events. The mechanisms are multiple and a firm diagnosis is often possible. However, further research is needed...
  96. ncbi [Why is allergic rhinitis currently at the centre of a debate?]
    Elie Serrano
    CHU Toulouse, Hopital Larrey, Service d ORL et de Chirurgie Cervico faciale, TSA 30030, F 31059 Toulouse 9, France
    Rev Laryngol Otol Rhinol (Bord) 124:269-75. 2003
  97. ncbi Systemic reactions during skin tests with beta-lactams: a risk factor analysis
    Hoai-Bich Co Minh
    J Allergy Clin Immunol 117:466-8. 2006
  98. ncbi Treating allergic rhinitis in pregnancy
    Vincent Piette
    Curr Allergy Asthma Rep 6:232-8. 2006
    ..There are no such data available for intranasal decongestants. Finally, pregnancy is not considered to be a contraindication for the continuation of immunotherapy...
  99. ncbi Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA)
    Jean Bousquet
    Allergy 58:192-7. 2003
  100. ncbi Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists
    Paolo Campi
    Allergy and Clinical Immunology Unit, Nuovo Ospedale San Giovanni di Dio, Florence, Italy
    Curr Opin Allergy Clin Immunol 7:393-403. 2007
    ..Some of these reactions are frequent but without consequences for the patients. Others are less frequent but potentially life-threatening, and they include allergic reactions...
  101. ncbi Recent advances in the diagnosis of drug allergy
    Antonino Romano
    Allergy Unit of Integrated Complex Columbus, Catholic University of Sacred Heart, Rome, Italy
    Curr Opin Allergy Clin Immunol 7:299-303. 2007
    ..Immediate reactions occur within 1 h; nonimmediate ones occur after more than 1 h...